医学
原发性中枢神经系统淋巴瘤
淋巴瘤
甲氨蝶呤
肿瘤科
耐火材料(行星科学)
脑脊液
疾病
随机对照试验
化疗
挽救疗法
内科学
神经毒性
外科
毒性
天体生物学
物理
作者
Christian Grommes,Lisa M. DeAngelis
标识
DOI:10.1200/jco.2017.72.7602
摘要
Primary CNS lymphoma (PCNSL) is a rare form of extranodal non-Hodgkin lymphoma that is typically confined to the brain, eyes, and cerebrospinal fluid without evidence of systemic spread. The prognosis of patients with PCNSL has improved during the last decades with the introduction of high-dose methotrexate. However, despite recent progress, results after treatment are durable in half of patients, and therapy can be associated with late neurotoxicity. PCNSL is an uncommon tumor, and only four randomized trials and one phase III trial have been completed so far, all in the first-line setting. To our knowledge, no randomized trial has been conducted for recurrent/refractory disease, leaving many questions unanswered about optimal first-line and salvage treatments. This review will give an overview of the presentation, evaluation, and treatment of immunocompetent patients with PCNSL.
科研通智能强力驱动
Strongly Powered by AbleSci AI